Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
43
NERV Quote, Financials, Valuation and Earnings
Last price:
$3.91
Seasonality move
:
-7.64%
Day range:
$3.51 - $3.93
52-week range:
$1.15 - $12.46
Dividend yield:
0%
P/E ratio:
2.45x
P/S ratio:
--
P/B ratio:
--
Volume:
42.3K
Avg. volume:
109.1K
1-year change:
63.18%
Market cap:
$27.3M
Revenue:
--
EPS (TTM):
-$1.85
Analysts' Opinion
-
Consensus RatingMinerva Neurosciences, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.50, Minerva Neurosciences, Inc. has an estimated upside of 15.39% from its current price of $3.90.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $3.90.
Fair Value
-
According to the consensus of 2 analysts, Minerva Neurosciences, Inc. has 15.39% upside to fair value with a price target of $4.50 per share.
NERV vs. S&P 500
-
Over the past 5 trading days, Minerva Neurosciences, Inc. has overperformed the S&P 500 by 20.29% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Minerva Neurosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Minerva Neurosciences, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Minerva Neurosciences, Inc. reported revenues of --.
Earnings Growth
-
Minerva Neurosciences, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Minerva Neurosciences, Inc. reported earnings per share of -$0.36.
Enterprise value:
74.9M
EV / Invested capital:
2.95x
Price / LTM sales:
--
EV / EBIT:
-0.58x
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-5.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-0.58x
Gross Profit (TTM):
-$5.4K
Return On Assets:
-40.95%
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
-44.73%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$29.6K | -$28.9K | -$5.4K | -$5.6K | -$1.4K | |
| Operating Income | -$21M | -$24.5M | -$14.6M | -$4.4M | -$2.8M | |
| EBITDA | -$21M | -$24.5M | -$14.6M | -$4.4M | -$2.8M | |
| Diluted EPS | -$4.72 | -$0.44 | -$1.85 | $2.97 | -$0.36 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $67.4M | $44.8M | $48.2M | $27.9M | $13M | |
| Total Assets | $97.6M | $59.8M | $63.1M | $42.8M | $28.1M | |
| Current Liabilities | $3.1M | $2.2M | $3.3M | $4.5M | $2.7M | |
| Total Liabilities | $69.5M | $74M | $83.2M | $64.5M | $62.7M | |
| Total Equity | $28.1M | -$14.2M | -$20M | -$21.7M | -$34.6M | |
| Total Debt | -- | $71.8M | $79.8M | $60M | $60M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.9M | -$20.4M | -$14.2M | -$4.4M | -$2.9M | |
| Cash From Investing | -$16.3K | -- | -- | -- | -- | |
| Cash From Financing | $19.6M | -- | -$45.2K | -- | -$45.2K | |
| Free Cash Flow | -$12.9M | -$20.4M | -$14.2M | -$4.4M | -$2.9M | |
NERV
Sector
Market Cap
$27.3M
$28.5M
Price % of 52-Week High
31.3%
51.82%
Dividend Yield
0%
0%
Shareholder Yield
36.11%
-1.4%
1-Year Price Total Return
63.18%
-21.29%
Beta (5-Year)
-0.396
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.74
200-day SMA
Buy
Level
$2.26
Bollinger Bands (100)
Buy
Level
1.85 - 3.85
Chaikin Money Flow
Sell
Level
-142.1M
20-day SMA
Sell
Level
$3.92
Relative Strength Index (RSI14)
Buy
Level
52.03
ADX Line
Buy
Level
36.66
Williams %R
Neutral
Level
-44.4444
50-day SMA
Buy
Level
$3.59
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
173.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-16.0673)
Sell
CA Score
(Annual)
Level (-7.4999)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-3.05)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Stock Forecast FAQ
In the current month, NERV has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NERV average analyst price target in the past 3 months is $4.50.
-
Where Will Minerva Neurosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Minerva Neurosciences, Inc. share price will rise to $4.50 per share over the next 12 months.
-
What Do Analysts Say About Minerva Neurosciences, Inc.?
Analysts are divided on their view about Minerva Neurosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Minerva Neurosciences, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Minerva Neurosciences, Inc.'s Price Target?
The price target for Minerva Neurosciences, Inc. over the next 1-year time period is forecast to be $4.50 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NERV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Minerva Neurosciences, Inc. is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NERV?
You can purchase shares of Minerva Neurosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Minerva Neurosciences, Inc. shares.
-
What Is The Minerva Neurosciences, Inc. Share Price Today?
Minerva Neurosciences, Inc. was last trading at $3.91 per share. This represents the most recent stock quote for Minerva Neurosciences, Inc.. Yesterday, Minerva Neurosciences, Inc. closed at $3.90 per share.
-
How To Buy Minerva Neurosciences, Inc. Stock Online?
In order to purchase Minerva Neurosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NERV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NERV
Sector
P/E ratio
2.45x
23.52x
PEG ratio
-0.01x
-0.01x
P/B ratio
--
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
NERV
Sector
Revenue growth
--
4.8%
Earnings growth
-112.19%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.14
-$0.20
Profitability
NERV
Sector
Profitability FY 2024
-$22.5K
$3.5M
Return on invested capital
-44.73%
-31.16%
Return on assets
-40.95%
-27.72%
Return on equity
--
-37.13%
Earnings Date
Last Earnings Date
Aug
5
Next Earnings Date
Dec
11
Estimated Next Earnings Date
Mar
12
Balance Sheet
NERV
Sector
Total cash
$12.4M
$27M
Short term investments
--
$25.7M
Total assets
$37.1M
$79.7M
Long term debt
$60M
$3.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
Buy
54
GDXU alert for Dec 10
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 4.83% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
